Mesa Labs Q4 Operating Income Surges 87%, Repays $14.7M Debt
MLAB sits 88% above its 52-week low of $55.45 on elevated volume (2.0× avg).
Summary
Mesa Laboratories announced strong fourth quarter and fiscal year 2026 results. The company reported an 87% increase in operating income for Q4 and repaid $14.7 million of debt, reducing its total net leverage ratio to 2.11. While revenues saw modest growth of 2.6% for the quarter and the Biopharmaceutical Development division faced challenges, overall profitability significantly improved. This follows the recent CEO transition, with Dr. Siddhartha Kadia currently conducting his 100-day review. The new CEO expects to provide rest-of-year guidance along with the release of H1 results.
At the time of this announcement, MLAB was trading at $104.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.6M. The 52-week trading range was $55.45 to $115.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.